No Data
No Data
Integral Molecular's Out-licensed Bispecific Antibody Enters Clinical Trial for Treating Solid Tumors
Express News | Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics to Participate in Upcoming Investor Conferences
Express News | D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target
12 Health Care Stocks Moving In Wednesday's Pre-Market Session